Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3

por Ali, Abir Salwa, Perren, Aurel, Lindskog, Cecilia, Welin, Staffan, Sorbye, Halfdan, Grönberg, Malin, Janson, Eva Tiensuu
Publicado 2020

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

por Ali, Abir Salwa, Grönberg, Malin, Langer, Seppo W., Ladekarl, Morten, Hjortland, Geir Olav, Vestermark, Lene Weber, Österlund, Pia, Welin, Staffan, Grønbæk, Henning, Knigge, Ulrich, Sorbye, Halfdan, Janson, Eva Tiensuu
Publicado 2018

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

por Ali, Abir Salwa, Langer, Seppo W., Federspiel, Birgitte, Hjortland, Geir Olav, Grønbæk, Henning, Ladekarl, Morten, Welin, Staffan, Weber Vestermark, Lene, Arola, Johanna, Osterlund, Pia, Knigge, Ulrich, Sørbye, Halfdan, Micke, Patrick, Grimelius, Lars, Grönberg, Malin, Tiensuu Janson, Eva
Publicado 2020

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

por Ali, Abir Salwa, Grönberg, Malin, Federspiel, Birgitte, Scoazec, Jean-Yves, Hjortland, Geir Olav, Grønbæk, Henning, Ladekarl, Morten, Langer, Seppo W., Welin, Staffan, Vestermark, Lene Weber, Arola, Johanna, Österlund, Pia, Knigge, Ulrich, Sorbye, Halfdan, Grimelius, Lars, Janson, Eva Tiensuu
Publicado 2017